



TSE EURL

Istituto Zooprofilattico Sperimentale del
Piemonte, Liguria e Valle d'Aosta – Torino

Istituto Superiore di Sanità – Roma

Proficiency testing for veterinary laboratories

Histopathology and immunohistochemistry interpretation (PT II 23)

Distribution date: October 2023

General comments

The TSE interpretation EQA is an exercise that allows all the NRLs to demonstrate their competence at reading stained/immunolabelled slides as part of their TSE diagnostic capability.

Attached below you will find a table summarising the results of the 2022 EQA round in conjunction with each participant ID.

The use of inconclusive/unsuitable for a case in which a definitive diagnosis is considered possible is not an 'incorrect' result in this context. A negative case called positive, or a positive case interpreted as negative are the only results which are considered 'incorrect'.

Correct and 'Safe' results are highlighted **green**. 'Incorrect' results are highlighted in **red**. Inconclusive or unsuitable returns are highlighted in **yellow**.

In the scrapie IHC category, readers were also invited to comment on whether the case is classical or atypical. Where a case is correctly diagnosed as positive, but subsequently misclassified, this has been identified on the table by highlighting the fonts of either "Pos-A" or "Pos-C" in **pink**.

Due to an error in the website form, the drop-down list did not allow scrapie to be classified in case number 3 during the PT II 2023. Even if many readers used the notes field for the classification, we cannot consider the "Pos" option as incorrect.

You should each have received email notification of your unique 'ObserverID'. You will need this to identify your results in the table. Please keep this information safely – your ID will NOT change with subsequent rounds. If you have misplaced your ID then please contact Dr Giuseppe Ru (giuseppe.ru@izsto.it) directly, and the information will be re-sent. If you know of new staff who require to be added to the programme, or existing members of staff who no longer need to participate in this EQA then please contact us.

It is important to review any cases for which you have given an incorrect answer (highlighted in **red and **pink**) and fill the 'Slide review form' (at the end of this document) and return it to Giuseppe Ru (giuseppe.ru@izsto.it) and a copy to Barbara Iulini (barbara.iulini@izsto.it).**



TSE EURL

Istituto Zooprofilattico Sperimentale del
Piemonte, Liguria e Valle d'Aosta – Torino

Istituto Superiore di Sanità – Roma

Please use one form for each misclassified case.

This confirms for the EURL (and your own third party quality systems) that appropriate follow-on review of sections has taken place with those readers who require to re-read particular slides.

Comments on the results

The summary table below has grouped the cases according to species so if you wish to refer back to a particular case, please check the case number carefully at the top of the table.

Thank you.

Date: 15/12/2023

Barbara Iulini.....

***Referent for Confirmatory Histopathology and Immunohistochemistry tests
Veterinary pathologist of Neuropathology Laboratory at IZSPLVA Italy***

Giuseppe Ru.....

Director of TSE EURL

Table 1. Results submitted by the participants in the PT II 23

Case number	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Test Type	IHC	IHC	IHC	IHC	H&E	IHC	H&E	IHC	IHC	H&E	IHC	IHC	IHC	H&E	IHC
Gold standard result	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Pos-A	Pos-C	Neg	Pos	Neg
Species	Ov	Bov	Ovine	Ov	Bov	Ov	Ov	Ov	Ov	Bov	Ov	Ov	Bov	Ov	Ov
IHC result of all H&E sections															
User ID															
84	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Inc	Pos-C	Neg	Pos	Neg
126	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Pos-A	Pos-C	Neg	Pos	Neg
140	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Inc	Pos-A	Pos-C	Neg	Pos	Inc
168	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Pos-A	Pos-C	Neg	Pos	Neg
172	Neg	Pos	Pos	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos	Neg
184	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Uns	Pos-A	Pos-C	Neg	Pos	Neg
227	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Pos-A	Pos-C	Neg	Pos	Neg
232	Neg	Pos	Pos	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Pos-A	Pos-C	Neg	Pos	Neg
261	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Pos-A	Pos-C	Neg	Pos	Neg
288	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Uns	Pos-A	Pos-C	Neg	Pos	Neg
307	Neg	Pos	Pos-C	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Inc	Pos-A	Pos-C	Neg	Pos	Neg
317	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Pos-A	Pos-C	Neg	Pos	Neg
340	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Pos-A	Pos-C	Neg	Pos	Neg
346	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Pos-A	Pos-C	Neg	Pos	Neg
364	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Pos-A	Pos-C	Neg	Pos	Neg
386	Uns	Pos	Pos	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Inc	Pos-A	Pos-C	Inc	Pos	Uns
393	Neg	Pos	Inc	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Uns	Pos-A	Pos-C	Neg	Pos	Neg
403	Inc	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Pos-A	Pos-C	Neg	Pos	Inc
407	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Uns	Pos-A	Pos-C	Neg	Pos	Neg
460	Neg	Pos	Pos	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Inc	Pos-A	Pos-C	Neg	Pos	Neg
494	Neg	Pos	Pos	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Inc	Pos-A	Pos-C	Neg	Pos	Neg
530	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Uns	Pos-A	Pos-C	Neg	Pos	Neg
546	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Uns	Pos-A	Pos-C	Neg	Pos	Neg
574	Neg	Pos	Pos	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Uns	Pos-A	Pos-C	Neg	Pos	Neg
627	Neg	Pos	Pos	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Pos-A	Pos-C	Neg	Pos	Neg
663	Neg	Pos	Pos	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Uns	Pos-A	Pos-C	Neg	Pos	Neg
668	Neg	Pos	Pos	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Uns	Pos-A	Pos-C	Neg	Pos	Neg
683	Neg	Pos	Pos-C	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Pos-A	Pos-C	Neg	Pos	Neg
685	Neg	Pos	Pos	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Inc	Pos-A	Pos-C	Neg	Pos	Neg
691	Neg	Pos	Pos	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Uns	Pos-A	Pos-C	Neg	Pos	Neg
710	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Inc	Pos-A	Pos-C	Neg	Pos	Neg
715	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Inc	Pos-C	Neg	Pos	Neg
725	Neg	Pos	Pos	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Inc	Inc	Pos-C	Neg	Pos	Neg
729	Inc	Pos	Pos	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Inc	Pos-A	Pos-C	Neg	Pos	Inc
743	Neg	Pos	Pos	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Inc	Pos-C	Pos-C	Inc	Pos	Inc
745	Neg	Pos	Pos	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Pos-A	Pos-C	Inc	Pos	Inc
863	Neg	Pos	Inc	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-C	Neg	Pos	Neg
924	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Pos-A	Pos-C	Neg	Pos	Pos-C
934	Neg	Pos	Pos-A	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Neg	Pos-A	Pos-C	Neg	Pos	Neg
962	Neg	Pos	Pos	Pos-C	Pos	Pos-C	Pos	Pos-C	Pos-C	Inc	Pos-A	Pos-C	Neg	Pos	Inc



TSE EURL

Istituto Zooprofilattico Sperimentale del
Piemonte, Liguria e Valle d'Aosta – Torino

Istituto Superiore di Sanità – Roma

Histopathology and immunohistochemistry interpretation EQA 2023

Distribution October 2023

Slide review form

Observer ID:	
Date of EQA round:	
Case number:	
Original observer result:	
Intended (gold standard) result:	
Date of review:	
Further observer comments following review:	